◎ Sugi Atlas

Atlas / Drug / Lypressin

Lypressin

drug
On this page

Also known as DiapidL-8LipresinaLypressineLysine vasopressinVasopressin pigSID144206455SID144206977[Lycine-8]-Vasopressinlysine-vasopressin

Summary

Lypressin (CHEMBL1200690) is an approved protein (ATC H01BA03) targeting AVPR1A, AVPR1B, and AVPR2.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Protein
  • ATC class: H01BA03
  • Targets: 3 (AVPR1A, AVPR1B, AVPR2)
  • Chemistry: 1056.2 Da · C46H65N13O12S2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1200690
NameLypressin
TypeProtein
Max phase4
FDA approvedno
PubChem CID644076
ATCH01BA03
Molecular formulaC46H65N13O12S2
Molecular weight1056.2
InChIKeyBJFIDCADFRDPIO-DZCXQCEKSA-N

SMILES: C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N

IUPAC name: (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide

Also known as: Diapid, L-8, Lipresina, Lypressin, Lypressine, Lysine vasopressin, Vasopressin pig, LYPRESSIN, SID144206455, SID144206977, [Lycine-8]-Vasopressin, lysine-vasopressin

Patent coverage: 919 distinct patent families (3,327 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
AVPR1AV1A receptorFull agonist8.64.6%P37288
AVPR1BV1B receptorFull agonist8.50.4%P47901
AVPR2V2 receptorFull agonist8.50%P30518

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 3 target gene(s): AVPR1A, AVPR1B, AVPR2.

Top Reactome pathways

8 total, by targets touching each:

PathwayTargetsGenes
Vasopressin-like receptors3AVPR1A, AVPR1B, AVPR2
G alpha (q) signalling events2AVPR1A, AVPR1B
Defective AVP does not bind AVPR1A,B and causes neurohypophyseal diabetes insipidus (NDI)2AVPR1A, AVPR1B
G alpha (s) signalling events1AVPR2
Vasopressin regulates renal water homeostasis via Aquaporins1AVPR2
Cargo recognition for clathrin-mediated endocytosis1AVPR2
Clathrin-mediated endocytosis1AVPR2
Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI)1AVPR2

Dominant GO biological processes

GO termTargets
regulation of systemic arterial blood pressure by vasopressin3
G protein-coupled receptor signaling pathway3
cellular response to hormone stimulus3
positive regulation of vasoconstriction3
signal transduction3
positive regulation of systemic arterial blood pressure2
positive regulation of cytosolic calcium ion concentration2
positive regulation of cell population proliferation2
telencephalon development2
transport across blood-brain barrier2
regulation of blood pressure2
positive regulation of blood pressure2
maternal aggressive behavior1
generation of precursor metabolites and energy1
negative regulation of female receptivity1

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

144 molecules share ≥1 primary target. Top 100 by shared-target count:

MoleculeSourceStatusShared targets
DESMOPRESSINChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR1B, AVPR2
OXYTOCINChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR1B, AVPR2
ATOSIBANChEMBLPhase 4 (approved)AVPR1A, AVPR1B, AVPR2
CARBETOCINChEMBLPhase 4 (approved)AVPR1A, AVPR1B, AVPR2
MOZAVAPTANChEMBLPhase 4 (approved)AVPR1A, AVPR1B, AVPR2
VASOPRESSINChEMBLPhase 4 (approved)AVPR1A, AVPR1B, AVPR2
NELIVAPTANChEMBLPhase 2AVPR1A, AVPR1B, AVPR2
ORNIPRESSINChEMBLPhase 2AVPR1A, AVPR1B, AVPR2
PECAVAPTANChEMBLPhase 2AVPR1A, AVPR1B, AVPR2
SELEPRESSINChEMBLPhase 2AVPR1A, AVPR1B, AVPR2
PIMOZIDEChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR2
RIFAMPINChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR2
TEGASERODChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR2
BALSALAZIDEChEMBLPhase 4 (approved)AVPR1A, AVPR2
BOSUTINIBChEMBLPhase 4 (approved)AVPR1A, AVPR2
CHLORHEXIDINEChEMBLPhase 4 (approved)AVPR1A, AVPR2
CONIVAPTANChEMBLPhase 4 (approved)AVPR1A, AVPR2
FLUSPIRILENEChEMBLPhase 4 (approved)AVPR1A, AVPR2
NITAZOXANIDEChEMBLPhase 4 (approved)AVPR1A, AVPR2
PYRVINIUMChEMBLPhase 4 (approved)AVPR1A, AVPR2
RIFAXIMINChEMBLPhase 4 (approved)AVPR1A, AVPR2
TOLVAPTANChEMBLPhase 4 (approved)AVPR1A, AVPR2
BALOVAPTANChEMBLPhase 3AVPR1A, AVPR2
LIXIVAPTANChEMBLPhase 3AVPR1A, AVPR2
OTILONIUM BROMIDEChEMBLPhase 3AVPR1A, AVPR2
BENZETHONIUMChEMBLPhase 2AVPR1A, AVPR2
DOMIPHENChEMBLPhase 2AVPR1A, AVPR2
RELCOVAPTANChEMBLPhase 2AVPR1A, AVPR2
AbirateronePubChemApprovedAVPR1A, AVPR2
acetylcysteinePubChemApprovedAVPR1A, AVPR2
Aclidinium BromidePubChemApprovedAVPR1A, AVPR2
AcyclovirPubChemApprovedAVPR1A, AVPR2
AfatinibPubChemApprovedAVPR1A, AVPR2
AllopurinolPubChemApprovedAVPR1A, AVPR2
AlmotriptanPubChemApprovedAVPR1A, AVPR2
AlogliptinPubChemApprovedAVPR1A, AVPR2
aminolevulinic acidPubChemApprovedAVPR1A, AVPR2
AnagrelidePubChemApprovedAVPR1A, AVPR2
ApixabanPubChemApprovedAVPR1A, AVPR2
AprepitantPubChemApprovedAVPR1A, AVPR2
BelzutifanPubChemApprovedAVPR1A, AVPR2
BosentanPubChemApprovedAVPR1A, AVPR2
ClofarabinePubChemApprovedAVPR1A, AVPR2
ClozapinePubChemApprovedAVPR1A, AVPR2
CrizotinibPubChemApprovedAVPR1A, AVPR2
DacarbazinePubChemApprovedAVPR1A, AVPR2
DesloratadinePubChemApprovedAVPR1A, AVPR2
Desoxycorticosterone PivalatePubChemApprovedAVPR1A, AVPR2
DidanosinePubChemApprovedAVPR1A, AVPR2
DihydroergotaminePubChemApprovedAVPR1A, AVPR2
ErythromycinPubChemApprovedAVPR1A, AVPR2
EthambutolPubChemApprovedAVPR1A, AVPR2
FidaxomicinPubChemApprovedAVPR1A, AVPR2
FulvestrantPubChemApprovedAVPR1A, AVPR2
GanciclovirPubChemApprovedAVPR1A, AVPR2
GefitinibPubChemApprovedAVPR1A, AVPR2
GlycopyrrolatePubChemApprovedAVPR1A, AVPR2
LeucovorinPubChemApprovedAVPR1A, AVPR2
LinagliptinPubChemApprovedAVPR1A, AVPR2
MethotrexatePubChemApprovedAVPR1A, AVPR2
OlanzapinePubChemApprovedAVPR1A, AVPR2
Olmesartan MedoxomilPubChemApprovedAVPR1A, AVPR2
PramipexolePubChemApprovedAVPR1A, AVPR2
PropoxyphenePubChemApprovedAVPR1A, AVPR2
PyrazinamidePubChemApprovedAVPR1A, AVPR2
RufinamidePubChemApprovedAVPR1A, AVPR2
saxagliptinPubChemApprovedAVPR1A, AVPR2
SildenafilPubChemApprovedAVPR1A, AVPR2
TadalafilPubChemApprovedAVPR1A, AVPR2
TafamidisPubChemApprovedAVPR1A, AVPR2
TamsulosinPubChemApprovedAVPR1A, AVPR2
Tiotropium Bromide MonohydratePubChemApprovedAVPR1A, AVPR2
ValacyclovirPubChemApprovedAVPR1A, AVPR2
ValganciclovirPubChemApprovedAVPR1A, AVPR2
CINACALCETChEMBL + PubChemPhase 4 (approved)AVPR2
AMIODARONEChEMBLPhase 4 (approved)AVPR2
AMOXAPINEChEMBLPhase 4 (approved)AVPR2
ARIPIPRAZOLEChEMBLPhase 4 (approved)AVPR1A
CLOTRIMAZOLEChEMBLPhase 4 (approved)AVPR2
DAUNORUBICINChEMBLPhase 4 (approved)AVPR1A
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)AVPR1A
EPALRESTATChEMBLPhase 4 (approved)AVPR1A
IDEBENONEChEMBLPhase 4 (approved)AVPR2
INDOCYANINE GREEN ACID FORMChEMBLPhase 4 (approved)AVPR1A
IPRINDOLEChEMBLPhase 4 (approved)AVPR2
ITRACONAZOLEChEMBLPhase 4 (approved)AVPR2
LASOFOXIFENEChEMBLPhase 4 (approved)AVPR2
MEFLOQUINEChEMBLPhase 4 (approved)AVPR2
NEBIVOLOLChEMBLPhase 4 (approved)AVPR2
NERATINIBChEMBLPhase 4 (approved)AVPR2
NIMESULIDEChEMBLPhase 4 (approved)AVPR2
PONATINIBChEMBLPhase 4 (approved)AVPR1A
RIMONABANTChEMBLPhase 4 (approved)AVPR1A
RITONAVIRChEMBLPhase 4 (approved)AVPR1A
SAQUINAVIRChEMBLPhase 4 (approved)AVPR1A
SERTINDOLEChEMBLPhase 4 (approved)AVPR2
SERTRALINEChEMBLPhase 4 (approved)AVPR2
SUNITINIBChEMBLPhase 4 (approved)AVPR2
TERFENADINEChEMBLPhase 4 (approved)AVPR2
TERLIPRESSINChEMBLPhase 4 (approved)AVPR1A

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 27

This page pulls from 27 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot